Personalized Cancer Screening
What is the procedure?
Cancer tissues from a surgical specimen are implanted into experimental hosts to establish first-generation grafts. The grafts are subsequently treated with a spectrum of anti-cancer drugs to determine which drug(s) are most effective. The results can usually be provided to patients and their oncologists whithin 5 to 8 weeks, before the initiation of therapy.
How will personalized drug screening benefit the patient?
In the treatment of cancer today, it is difficult to predict whether a particular anti-cancer drug will be effective for a patient’s cancer. Each cancer is unique and a particular drug might be effective for one cancer but not for another of the same type. Due to the potential toxicity of anti-cancer drugs, treating a patient with multiple drugs is not feasible and it is therefore critical that the most effective drug regimen is used. This can be determined via Personalized Drug Screening of the patient's cancer grafts. In addition, transplantable cancer tissue lines developed from the patient's cancer can be banked for future studies and testing of new drug regimens.
Who is involved?
The procedure requires a surgical specimen from the patient cancer, but no subsequent patient involvement is necessary. This procedure will be a collaboration between the LTL, the patient, and the surgery/oncology team.